Marker Therapeutics Inc (MRKR)

[lasers]

NetworkNewsWire Announces Publication of Discussion on the Potential of Immunotherapies for Cancer Treatment
MARKET WIRE 8:30 AM ET 3/24/2017
Symbol Last Price Change
TPIV 4.7672up +0.0372 (+0.79%)
QUOTES AS OF 09:53:54 AM ET 03/24/2017
NEW YORK, NY -- (Marketwired) -- 03/24/17 -- NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring TapImmune, Inc.(TPIV) , an NNW client focused on leading the field of oncology with its next-generation T-cell vaccines and novel immunotherapy platforms.

The publication, entitled, "Innovative Immunotherapies Emerging as the Cancer Treatments of the Future," provides insight into the prevalence of cancer worldwide and how several innovative companies are advancing their immune-oncology therapies to fight the disease.

To view the full publication visit: https://www.networknewswire.com/innovative-immunotherapies-emerging-cancer-treatments-future/

"According to the World Health Organization (WHO), cancer is the second-leading cause of death worldwide, responsible for about 8.8 million deaths in 2015. ... Subsequently, annual cancer drug spending is also on the rise, expected to exceed $150 billion by 2020, according to a report by IMS Health Holdings, Inc. The 10.5 percent increase is largely driven by the emergence of new immunotherapies that are designed to help cancer patients' immune systems learn how to attack tumors. An innovative immunotherapy approach comes from TapImmune, Inc.(TPIV) , whose next-generation technology can overcome the deficiencies of earlier vaccines and become a powerful therapy on its own or in combination with other types of immunotherapies. ... In addition to its T-cell vaccine candidates, TapImmune(TPIV) is developing a proprietary and groundbreaking peptide expression system meant to make DNA-based immunotherapy more effective. PolyStart™ is significantly more efficient than existing antigen expression technologies, as it can enhance the recognition of target cells by the immune system, making them easier to be identified and eliminated."

About TapImmune, Inc.(TPIV)
TapImmune, Inc. (TPIV) is a leader in the immunotherapy of woman's cancers advancing multiple Phase 2 and Phase 1b/2 clinical studies for the treatment of ovarian and breast cancer. The company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient's killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The company's technologies may be used as stand-alone medications or in combination with current treatment modalities.

For more information, visit www.tapimmune.com